A randomised, double-blind, placebo-controlled phase 2 trial of FOL-005 to investigate efficacy on hair growth on scalp skin in healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs FOL 005 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Follicum AB
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Feb 2018 According to a Follicum AB media release, this study is scheduled to commence during the first quarter of 2018 with recruitment of patients from both Berlin and Hamburg.
- 13 Feb 2018 According to a Follicum AB media release, the company has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence this trial in Germany. Trial completion and results are expected in 2018. The trial will be run in collaboration with the Clinical Research Center for Hair and Skin Science (CRC) in Berlin and bioskin, Hamburg, Germany.